You turned 75 and the reminder card still arrives. Your doctor says it is up to you. That is not a dodge. It is an accurate summary of the evidence, and it puts a genuinely difficult decision in your hands with very little to guide it.
Here is what is actually known, what is not, and the specific numbers that make the trade-off concrete.
The short answer
There is no guideline that tells you to stop at a particular age. The major US bodies converge on the same framing: screening after 75 should be decided by health status and life expectancy, not by the birthday.
The practical threshold most groups use is roughly 10 years of expected remaining life. Above that, screening likely still helps. Below it, screening is more likely to find a cancer that would never have troubled you than to add time to your life.
What do the guidelines actually say?
Three positions, and they are less contradictory than they first appear.
US Preventive Services Task Force (2024). The current recommendation gives biennial screening mammography a Grade B for women aged 40 to 74, concluding with moderate certainty that it has a moderate net benefit. For women 75 and older it issues a Grade I statement: the evidence is insufficient to determine the balance of benefits and harms. An I statement is not a recommendation against screening. It is a declaration that the Task Force cannot say either way.
American Cancer Society. Screening should continue as long as a woman is in good health and is expected to live at least 10 more years. The ACS notes that millions of women over 75 are in very good health with many years ahead, during which breast cancer risk remains high.
American College of Radiology and Society of Breast Imaging. Annual screening should continue past 74 with no upper age limit unless severe comorbidities limit life expectancy, with a working threshold of less than 5 to 7 years of expected remaining life.
All three make the same move: they replace an age cutoff with a life-expectancy judgment. They differ mainly in where they set that threshold and how strongly they lean toward continuing.
Why is there no clear answer?
Because the studies were never run. The randomized trials that established mammography's benefit did not enroll women 75 or older. There are no randomized clinical trials in this age group at all.
What exists instead is observational data and simulation modeling. Observational data in older women is badly confounded, because the women who continue screening into their late 70s and 80s tend to be healthier than those who stop. That difference alone makes screening look more effective than it is.
Simulation models fill the gap by projecting outcomes from what is known about tumor growth, competing mortality, and treatment effects. They are the best available evidence, and they are still models.
What does the modeling data show?
The most directly relevant analysis is van Ravesteyn and colleagues, published in the Journal of the National Cancer Institute in 2015, using three independent CISNET simulation models.
Overdiagnosis, per 1,000 screens:
- Age 74: about 1.2 to 5.0 cases
- Age 80: about 1.8 to 6.0 cases
- Age 90: about 3.7 to 7.5 cases
Life-years gained, per 1,000 screens:
- Age 74: 7.8 to 11.4
- Age 80: 4.8 to 7.8
- Age 90: 1.4 to 2.4
Read those two lists together and the shape of the problem is clear. Harm rises with age while benefit falls. The authors found that at roughly ages 90 to 92, harms outweighed benefits across all three models.
Between 75 and 90, the ratio is still favorable on average but narrowing. That is precisely the range where an individual answer beats a population answer.
Where the 10-year life expectancy rule comes from
It is a timing argument, not an arbitrary round number.
A cancer found on a screening mammogram is typically small and slow. The gap between finding it early and the point where it would have caused symptoms and been treated anyway is measured in years. It takes roughly a decade before a screen-detected breast cancer produces a measurable survival difference at the population level.
If your expected remaining life is shorter than that horizon, the screening cannot deliver its main benefit. It can still deliver its costs: the callback, the biopsy, the diagnosis, the treatment, and the anxiety attached to all of it. Our guides to what happens after a callback and false positives cover what that process actually involves.
An important qualifier: life expectancy at 75 is not short. A woman in good health at 75 in the United States has, on average, well over a decade of life remaining. The 10-year rule excludes far fewer 75-year-olds than people assume.
What overdiagnosis means at this age
Overdiagnosis is the detection of a cancer that is real under the microscope but would never have caused symptoms or shortened your life. It is not a false positive and not an error in reading the film. The cancer is genuinely there.
The reason it matters more with age is competing mortality. A slow-growing tumor found at 82 has fewer years in which to become a problem than the same tumor found at 55. Once found, though, it is almost always treated, because there is no reliable way to identify in advance which cancers would have stayed quiet.
That treatment carries real costs at older ages: surgery, radiation, endocrine therapy, and their side effects, all delivered for a cancer that might never have mattered. This is the harm that grows.
Does your health status change the stopping age?
Substantially, and this is the most useful finding in the modeling work.
The 2015 JNCI analysis compared benefit-to-harm ratios across comorbidity levels and found that screening until roughly ages 76, 74, 72, and 66 produced comparable ratios for women with no, mild, moderate, and severe comorbidities respectively.
A 10-year swing based on health status, not age. A robust 78-year-old with no significant conditions sits in a different place than a 70-year-old managing heart failure and COPD. The chronological number is the weakest input in the decision.
Questions worth asking your doctor
This is a shared decision by design, which means you need specific questions rather than a yes or no:
- Given my other conditions, what is a realistic estimate of my life expectancy? Uncomfortable to ask, and the single most decision-relevant number.
- If a small cancer were found, would I want treatment? If the honest answer is no, screening has little to offer.
- How dense is my breast tissue? Density falls with age for most women, which changes mammogram accuracy. Our guide to dense breast tissue covers the implications.
- Am I at above-average risk? A personal history, a strong family history, or a known genetic variant shifts the calculation toward continuing.
- Would every two years be reasonable instead of every year? Biennial screening captures most of the benefit with roughly half the callbacks and biopsies.
There is no wrong answer here, which is what makes it hard. A woman of 80 in excellent health who would pursue treatment has a good case for continuing. A woman of 78 with serious heart or lung disease who would decline treatment has a good case for stopping. Both are following the evidence.
For how the broader adult screening schedule fits together, our sister site covers preventive screenings by decade. For where the schedule begins, see when to get your first mammogram.
Last updated: August 2026. This article is for informational purposes only and does not constitute medical advice. Screening decisions after 75 should be made with your own physician, based on your health status and preferences.